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Background: Although the safety and effectiveness of Drug-Eluting Stents (DES) has been
established extensively, reports on long term clinical outcome with angiographic findings
in patients with long coronary artery lesions are not many.
Methods: In this single-center prospective registry of 100 patients, a total of 110 denovo long
lesions (>20 mm) were treated with Resolute Zotarolimus Eluting Stent (R-ZES). The pa-
tients were followed up clinically at 3, 6 and 12 months and follow up coronary angiog-
raphy was performed at 9-months. The primary end point was one year rate of target
lesion failure (TLF) which is a composite of cardiac death, target lesion myocardial
infarction or ischemia driven target lesion revascularization (TLR). The secondary end
points included definite or probable stent thrombosis, 9-month angiographic restenosis
and late lumen loss.
Results: The mean age of patients was 58.7 ± 9.50 years with prevalence of diabetes as high
as 60%. The mean lesion length was 24.67 ± 4.87 mm with a mean reference vessel
diameter of 2.85 ± 0.32 mm and 67.3% were Type C lesions (ACC/AHA classification). Two
patients died during follow-up, of which one was non-cardiac death. One patient had
target vessel myocardial infarction and five patients (4.5%) had ischemia driven TLR. The
incidence of TLF was 6.36%. Binary restenosis was seen in 7 out of 93 lesions (7.5%). Median
late lumen loss at 9 month was 0.22 mm. No stent thrombosis was noted in the study.
Conclusion: Implantation of R-ZES in real-world patients with long coronary artery lesions is
safe with comparable efficacy to what is observed in the treatment of less complex lesions.
Copyright © 2015, Cardiological Society of India. All rights reserved.tre, Ananthapuri Hospitals and Research Institute, Thiruvananthapuram, Kerala 695 024,
.uk (C.G. Bahuleyan).
ociety of India. All rights reserved.
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Long coronary artery lesions comprise up to 20% of percuta-
neous coronary intervention (PCI) and it is an important
determinant of unfavorable outcomes after stent implanta-
tion.1 Although widespread use of early generation drug
eluting stent (DES) has resulted in beneficial outcome of PCI in
general, the overall major adverse cardiac events (MACE) in
the treatment of long lesion remained relatively high.2 Use of
new generation DES of 38 mm length to cover long lesion has
been found to be safe and efficacious during one year follow-
up.3,4 Various randomized clinical trials and registries have
shown better safety and efficacy outcomes with the use of
new generation DES in treating long lesions with either single
or overlapping stents in comparison to first generation DES.5,6
However there is paucity of data on the outcomes of
treating long lesions with DES in a real world scenario,
involving patients with different clinical presentations, risk
factors and varying complexity of lesions. This prospective
study was undertaken to evaluate safety and efficacy and 12
month follow-up outcome of Zotarolimus Eluting Stent (PSE-
ZES) in treating a cohort of patients with long lesions who
present for intervention in day-to-day clinical practice.2. Materials and methods
PSEZES was a single centre, prospective, open label, non-
randomized study of Resolute Zotarolimus Eluting Stent (R-
ZES) in long coronary artery lesion, conducted at Cardiovas-
cular Centre of Ananthapuri Hospitals and Research Institute,
Thiruvananthapuram, Kerala, India. The studywas conducted
from June 2010 to September 2012 after getting the approval of
Institutional Ethics Committee. All patients provided written
informed consent for participation in the study.
This study included male or female patients >18 years of
age with Stable Ischemic Heart Disease (SIHD) or acute coro-
nary syndrome (ACS). Patients with ST-segment elevation
myocardial infarction (STEMI) undergoing primary PCI,
myocardial infarction (MI) within 72 h, cardiogenic shock, left
ventricular ejection fraction less than 30%, stroke within 6
months, severe renal or hepatic failure, known hypersensi-
tivity to Zotarolimus or other drugswhich could be used in the
study, coagulopathy, and patients not willing to sign consent
form, were excluded from the study.
The angiographic inclusion criterion was a target lesion of
more than 20 mm in length with a diameter stenosis of 50%.
The stent length was chosen to adequately cover the lesion,
extending 2e4 mm beyond the proximal and distal ends. All
patientswere started on dual antiplatelets and other guideline
recommended drugs. PCI was performed as per standard
protocol. Eighty percent of the PCI were done through radial
access. Pre dilation of the lesion was done in majority of the
cases and high pressure post dilatation of the stent was done
in all cases. A 12-lead ECG, serum concentration of creatine
kinase and its MB isoenzyme were measured before stenting
and twice after stenting with 8 h interval.
After discharge from the hospital, patients were followed
up clinically at 3, 6 and 12 months. Follow up Coronaryangiography was performed at 9-month. Clinical and angio-
graphic follow up of patients is shown in Fig. 1.3. Study end points
The primary endpoint was target lesion failure (TLF) at one
year after the procedure, a composite of cardiac death, target
vessel myocardial infarction or target lesion revascularisation
(TLR) by percutaneous or surgical methods. Secondary end
points included 9-month angiographic binary restenosis, 9-
month angiographic in-stent late loss and definite or prob-
able stent thrombosis (ST). All deaths were considered cardiac
unless an unequivocal non-cardiac cause could be estab-
lished. A diagnosis of MI was based on the appearance of new
Qwave or ST changes in at least 2 contiguous leads in the post
procedure ECG or an elevation of creatine kinase MB concen-
tration >3 times the upper limit of normal following the PCI.
Revascularization of the target lesion was considered
ischemia driven if there was 50% diameter stenosis of the
target lesion with ischemic signs or symptoms or diameter
stenosis 70% with or without documented ischemia. Stent
thrombosis was defined as definite or probable by Academic
Research Consortium definition.7
Coronary angiograms were recorded digitally at baseline,
immediately after the procedure and at 9-months follow up,
using Siemens AXIOM artis Cath Lab system. Off-line QCA
analysis was performed with an automatic edge-detection
algorithm (CAAS II systemic, Pie Medical, Maastricht, The
Netherlands) as described before.1,8 Secondary endpoints of
the study like binary restenosis was defined as >50% diameter
stenosis over the entire stent length and its 5 mm proximal
and distal margins on follow up and late luminal loss was
calculated as the difference betweenminimal lumen diameter
(MLD) post intervention and at follow up. Device success was
defined as a final stenosis of <30% of the vessel diameter after
implantation of the assigned stent.4. Data analysis
Data was entered and analyzed using Microsoft Excel. Quali-
tative variables included those related to risk factors, previous
history, clinical presentation and lesion details and were
expressed as frequencies and percentages. Quantitative
variables-mainly angiographic details at three time-points
were expressed as median and Inter-quartile Range (IQR).5. Results
Between 01 June 2010 and 19 Sep 2012, 100 patients were
recruited, in whom 110 long lesions were treated. The mean
age of patients was 58.7 ± 9.5 years. The baseline clinical
characteristics are shown in Table 1. It is noteworthy that
diabetes mellitus was present in 60% of the population and
59% had ACS at presentation. This in general, represents the
clinical features of patients undergoing PCI in our centre with
high proportion of ACS and diabetes mellitus. The lesion dis-
tribution is shown in Fig. 2, lesion details and stent details in
Fig. 1 e Patient follow-up in PSEZES trial.
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classification), 68.2% were <2.75 mm in diameter and 40.9%
were25mm in length. 55.4% lesions received stents30mm
in length.Major side branchwas present at the lesion site in 54
(49%) lesions. Out of 54 bifurcation lesions 41 required an
additional guide wire to protect the side branch, but no lesion
required a side branch stenting. Therewas no overlap stenting
in any lesions. The rate of device success was 100%. Therewas
no significant peri-procedural bleeding or in-hospital death.
Clinical follow-up was 100% as per scheduled intervals.
Eighty four patients underwent follow-up coronary angiog-
raphy. Two patients died during the follow-up, of which one
was non-cardiac death resulting from sepsis during hemodi-
alysis. One patient had target vessel myocardial infarction.
Five patients (4.5%) had ischemia driven TLR. The incidence of
TLF was 6.36% (Fig. 3). Nine-month follow-up angiographic
analysis of 93 study stents in 84 patients showed binaryTable 1 e Baseline clinical characteristics of the patients
(n ¼ 100).
Characteristics Value
Mean age in years 58.7 ± 9.5
Male 85%
Body-mass index (in kg/m2) 32.29
Risk factors
Obesity 88%
Diabetes mellitus 60%
Hypertension 60%
Dyslipidemia 38%
Smoking 26%
Previous history
Previous myocardial infarction 33%
Previous coronary angioplasty 11%
Previous bypass surgery 4%
Congestive Heart Failure 3%
Prior stroke(before 6 months) 3%
Peripheral arterial disease 1%
Clinical presentation
ACS 59%
Chronic stable angina 31%
Inducible ischemia 10%restenosis in 7 patients (7.5%), with a median late lumen loss
of 0.22 mm. There was no significant difference in target
lesion failure, or late lumen loss across different stent sizes or
diabetic vs. non-diabetic group. No stent thrombosis was
noted in this study. Angiographic details are given in Table 3.6. Discussion
Long coronary artery lesions constitute an important sub-
group of PCI patients who are at increased risk for restenosis
and adverse clinical events on follow up. The length of coro-
nary lesion has been a predictor of restenosis after balloon
angioplasty. In a cohort of patients with long lesions (>15mm)
use of baremetal stents (BMS) reduced the incidence of binary
restenosis compared to balloon angioplasty (36.9% vs. 27.9%
p < 0.001). Among patients treated with BMS, lesion length,
use of multiple stents and overlapping stents were found as
independent predictors of restenosis. Patients with long le-
sions showed more late lumen loss than those with short le-
sions (1.29 þ 0.89 vs. 1.07 þ 0.77 mm p < 0.001).9 Randomized
controlled trials have shown that, early generation DES have
resulted in considerable reduction in restenosis and the need
for repeat revascularization compared to BMS. TAXUS VILCX
11%
RCA
23%
LAD
66%
Fig. 2 e Lesion distribution (n ¼ 110). RCA-Right coronary
artery; LCX-Left circumflex artery; LAD-Left anterior
descending artery.
Table 2 e Lesion and stent details (n ¼ 110).
Details Value
Lesion length (mm)
20e25 mm 59.1%
25e30 mm 21.8%
30e35 mm 15.4%
>35 mm 3.6%
Mean lesion length 24 mm
Lesion characteristics
Eccentric lesions 97.2%
Moderate tortuosity 6.3%
<45 degree angulations 83.6%
Irregular contour 92.7%
Calcification 13.6%
Total occlusion 12.7%
Ostial lesions 7.2%
Thrombus 3.6%
Lesion class C 67.3%
Bifurcation 49%
Lesion distribution across vessels
Proximal LAD 40%
Mid LAD 16.4%
Distal LAD 7.8%
Diagonal 2.7%
Proximal LCX 4.5%
Distal LCX 2.7%
OM 3.6%
Proximal RCA 11.8%
Mid RCA 6.4%
Distal RCA 2.7%
RPLB 1.8%
Stent length
24 mm 44.5%
30 mm 34.5%
38 mm 20.9%
Table 3 e Angiographic details.
Numbers Median IQR
Mean RVD in mm
Pre procedure 110 2.8 2.67e3.18
Post procedure 110 3.06 2.9e3.33
At 9 months 93 3.08 2.9e3.36
Lesion length in mm 110 23.76 20.43e26.64
Diameter stenosis in %
Pre procedure 110 83.0 78.0e88.0
Post procedure 110 11.0 8.0e13.0
At 9 months 93 20.0 15.0e26.5
MLD in mm
Pre procedure 110 0.47 0.32e0.64
Post procedure 110 2.72 2.55e2.97
At 9 months 93 2.45 2.18e2.69
Late loss in mm (at 9 months)
Total population 110 0.22 0.13e0.415
Diabetics 66 0.3 0.15e0.56
Non-diabetics 44 0.2 0.12e0.46
38 mm stents 23 0.24 0.15e0.36
<38 mm stents 87 0.22 0.13e0.38
Stents 2.75 mm 45 0.23 0.14e0.49
Stents >2.75 mm 65 0.22 0.13e0.40
i n d i a n h e a r t j o u r n a l 6 7 ( 2 0 1 5 ) 2 3 3e2 3 8236study revealed a TLR rate of 9.1% in the Paclitaxel Eluting Stent
(PES) group compared to 19.4% in the BMS group (p ¼ 0.0027).
Mean lesion length in the study was 20.6 mm and mean stent
length was 33.4 mm 55.6% of the lesions were type C of the
ACC/AHA classification. Binary restenosis was 32.9% in the
BMS group and 9.1% in the PES group.2
In PSEZES trial themean lesion lengthwas 24 ± 4.8mmand
67.3% were having Type C lesions. Use of new generation R-Fig. 3 e Primary end points at one year in PSEZES (n¼ 110).
MI-Myocardial Infarction; TLR-Target lesion
revascularization; TLF-Target lesion failure.ZES resulted in a relatively lower binary restenosis of 7.5%.
Mean stent length used in our study was 28.74 ± 5.2 mm and
overlapping stents were avoided. Schoefer et al compared
Sirolimus Eluting Stent (SES) with BMS in lesions longer than
15mm lengthwith a vessel diameter of 2.5e3.0mmand found
lower binary restenosis rate with SES (5.9% vs. 42.3%
p ¼ 0.0001) and fewer MACE rate at 9 months (8.0% vs. 22.6%
p ¼ 0.0002) mainly due to a reduction in the need for TLR (4.0%
vs. 20.9% p < 0.0001).10
The LONG-DES registry and LONG-DES II randomized trial
also revealed superiority of SES over PES in reducing angio-
graphic restenosis in patients with long lesions.11,12 LONG-
DES III Trial randomized patients with long lesion (>25 mm)
to treatment with Everolimus Eluting Stent (EES) and SES. EES
implantation was associated with greater angiographic in-
segment late loss and higher rate of in-segment restenosis
compared with SES implantation. However there was no dif-
ference in the clinical outcomes noted.13 Although the inclu-
sion criteria of lesion length in our study was >20 mm in
length, 45 lesions (40.9%) were >25 mm in length.
LONG-DES IV Trial compared R-ZES with SES in native long
coronary lesions and found no significant difference in 9
month in-segment and in-stent late luminal loss, binary
restenosis, and clinical events between the two stents.5 In
LONG-DES IV trial 9 month angiographic in-stent binary
restenosis was 4% and late lumen loss was 0.26 ± 0.36 mm in
the R-ZES groupwhichwas relatively less compared to PSEZES
outcome. But it should be noted that the R-ZES cohort of LONG
DES IV had only 27.2% diabetics compared to 60% diabetics in
the PSEZES trial. Similarly mean RVD of the R-ZES group was
3.25 ± 0.47 mm compared to 2.84 ± 0.32 mm in the PSEZES
patients. So relatively high late lumen loss in PSEZES trial
could be due to the fact that majority of the patients are dia-
betic with small vessels.
New generation DES in general are associated with better
clinical and angiographic outcomes in long lesions even while
covering the entire lesion with long stents. A stent length
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rate of TLR and ST in patients treated with first-generation
DES but not with New-Generation DES.14 In our study, 61 le-
sions (55.4%) received stents >30 mm in length and no ST was
observed and TLR was only 4.5%. Lee et al reported on the use
of 38 mm R-ZES in treating long lesions, with low rate of TLF
and ST and no difference in outcomes between patients with
and without diabetes.6 In our study 23 patients received
38mm stent, but no ST was noted. Jon Suh et al observed that,
stent length was an independent predictor of ST. The stent
length >31.5 mm was associated with higher rates of ST (4.05
vs. 0.7% p < 0.001), death (5.2% vs. 3% p ¼ 0.005) and MI (2.4%
vs. 0.7% p ¼ 0.001) at 3 years as compared with stent
length<31.5 mm.15 Moreno et al documented the correlation
between ST and stent length in a previous meta-analysis.16
R-ZES has better biocompatibility, drug-release kinetics
and anti restenotic efficacy compared to previously intro-
duced Zotarolimus Eluting Stent (ZES).17,18 R-ZES and EES has
shown similar safety and efficacy during a followup of 4-years
in the Resolute All Comers trial.19 In our study, R-ZES in a
cohort of patients with significant ischemia and at least one
long lesion requiring stenting, showed favorable clinical and
angiographic results during a follow up of one year. Among
110 lesions with a mean length of 24.67 ± 4.87 mm and mean
vessel diameter of 2.85 ± 0.32 mm, one-year rate of TLF was
6.36% and binary restenosis was 7.5%.
Our study is unique compared to the similar studies of long
lesions because of the high prevalence of Diabetes mellitus.
Patients in trial, with high prevalence of risk factors and varied
clinical presentations represent thosewhoareusually referred
for PCI in this part of the world. However these observations
should be confirmed in a trial with large number of similar
patientswith longer termof followup.Another notable finding
in our cohortwas the small vessel size.Mean RVDof thewhole
cohort was 2.84 ± 0.32mmwhile in the diabetic patients it was
only 2.4 ± 0.43 mm. Small vessels and long lesions still remain
to be a challenge even in the DES era. Promising results with
new generation Platinum Chromium Everolimus Eluting Stent
with low rate of TLFhas beenobserved in this groupof patients
in a recent study.20 With increasing number of diabetic pa-
tients being considered for PCI in our population, interven-
tional strategy for small vessels with long and diffuse disease
will be the focus of further study.7. Conclusion
Implantation of R-ZES to treat long coronary artery lesions in a
group of real-world patients with multiple risk factors and
varied clinical presentations has been found to be safe and
efficacious. The Device success was 100% and 1-year MACE
rate of death, MI, TLR was low with no incidence of ST. The
binary restenosis and angiographic in-stent late lumen loss
was consistent with previous results.8. Limitations
This is a single centre study with relatively short-term follow-
up of 12 months. The number is small to make any sub groupanalysis. Even though we planned for 100% angiographic
follow up, we were able to achieve only 84%. However we
consider this reasonable in the light of the fact that similar
studies quote around 70% follow up angiograms.Conflicts of interest
All authors have none to declare.
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